eyal

­

About eyal

This author has not yet filled in any details.
So far eyal has created 81 blog entries.

Biocon and Quark Pharmaceuticals Collaborate to Develop Novel siRNA based Therapeutics

December 18th, 2013|

Bangalore, India, and Fremont, CA, December 18, 2013  

Biocon Ltd, Asia’s premier biotechnology company, and Quark Pharmaceuticals, Inc,. a world leader in the discovery and development of siRNA-based therapeutics, announced today that they have entered into a Licensing  & Collaboration agreement for the development of  a range of siRNA ( small interfering RNA)  based novel therapeutics.

This […]

Quark Pharmaceuticals Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007

January 4th, 2012|

Fremont, CA January 4, 2012, — Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced interim results from the first two cohorts of its Open Label, first-in-human Phase I clinical study of QPI-1007, the Company’s proprietary synthetic siRNA drug candidate for ocular neuroprotection, in patients with recent onset […]

In a Phase 2 Study PF-04523655 (RTP801I-14) Showed Improved Vision Over Standard of Care in Patients with Diabetic Macular Edema at 12 Months

March 18th, 2011|

Fremont, CA March 18, 2011, – Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in the discovery and development of RNAi-based therapeutics, , today announced that it has received results from a prospective randomized Phase 2 trial, the DEGAS study. This study evaluated the safety and efficacy of PF-04523655 (RTP801I-14) in patients with diabetic macular edema […]

Rutgers Offers Hope in New Treatment for Spinal Cord Injuries

March 3rd, 2011|

May 03, 2011, – Rutgers researchers have developed an innovative new treatment that could help minimize nerve damage in spinal cord injuries, promote tissue healing and minimize pain.
After a spinal cord injury there is an increased production of a protein (RhoA) that blocks regeneration of nerve cells that carry signals along the spinal cord and […]

Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007

October 20th, 2010|

Dosing Initiated at Highest Planned Dose in Chronic Nerve Atrophy Patient Group

Fremont, CA October 20, 2010, – Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in the discovery and development of RNAi-based therapeutics, today announced it has dosed the first patient with recent onset of non-arteritic anterior ischemic optic neuropathy (NAION) in its ongoing Phase I study […]

Quark Pharmaceuticals and Major Pharmaceutical Company Enter into Licensing Option Agreement for the p53 Suppressor Drug QPI-1002, the First siRNA Administered Systemically in Human

August 18th, 2010|

 FREMONT, CA., Aug. 18,2010  Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.

Quark will receive […]

Nitto Denko and Quark Pharmaceuticals to Enter into Collaboration to Develop a Novel siRNA Anti-fibrotic Drug

July 15th, 2010|

Nitto Denko to use its specialty delivery vehicle, targeting technology for fibrosis with novel therapeutic concepts together with Quark proprietary RNAi technology, novel structures with FTO and siRNA clinical development expertise to file for an IND for a new anti-fibrotic drug

Osaka, Japan and Fremont, CA, July 15, 2010 –  Nitto Denko Corporation, Japan’s leading diversified materials […]

Quark Pharmaceutical’s QPI-1007 Exhibits Neuroprotective Effects in Glaucoma Model

June 28th, 2010|

FREMONT, Calif., Jun 28, 2010 –  Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced results from a second study of QPI-1007, a neuroprotective siRNA drug, in rat ocular hypertension model of glaucoma, conducted by Prof. Adriana Di Polo of the Department of Pathology and Cell Biology, Université de […]

Quark Pharmaceuticals Announces Presentations of its Two siRNA Drug Candidates at Glaucoma & Retinopathies 2010

June 24th, 2010|

FREMONT, Calif., Jun 24, 2010 –  Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that two of its siRNA drug candidates were featured in the following two presentations at the Glaucoma & Retinopathies 2010 conference, which was held June 21-22, 2010 in London, UK:

“QPI-1007, an ocular neuroprotective siRNA […]

Quark Granted European Orphan Drug Status for QPI-1002 for the Prophylaxis of Delayed Graft Function in Kidney Transplant Patients

June 15th, 2010|

FREMONT, Calif., Jun 15, 2010 –  Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that the European Commission has granted Orphan Medicinal Product Designation for QPI-1002 (also referred to as “I5NP”) for the prophylaxis of delayed graft function (DGF) in kidney transplant patients. QPI-1002 is a synthetic siRNA […]